Long-term Outcome of the REMAGUS 02 Trial, a Multicenter Randomised Phase II Trial in Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy With or Without Celecoxib or Trastuzumab According to HER2 Status

The REMAGUS-02 multicenter randomized phase II trial showed that the addition to neoadjuvant chemotherapy of trastuzumab in patients with localized HER2-positive breast cancer increased the pathological complete response rate and that the addition of celecoxib in HER2-negative cases did not increase the pathological complete response rate. This article the long-term follow-up results for disease-free survival and overall survival, indicating that celecoxib combined with neoadjuvant chemotherapy provided neither pathological complete response rate benefit nor survival benefit in patients with HER2-negative breast cancer.

 Eur J Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.